KL-6 as a Biomarker of Interstitial Lung Disease Development in Patients with Sjögren Syndrome: A Retrospective Case-Control Study.

J Inflamm Res · 2022 · PMC9005069 · PMID 35422651

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not achieve significanceno p-value reported

Serum KL-6 in both immunoassays was elevated in patients with pSS who developed ILD during follow-up, but the LETIA did not achieve significance.

also in 1,397 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.